The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

GLP-1 drugs such as Wegovy and Ozempic (semaglutide) and Zepbound (tirzepatide) may offer benefits that extend beyond aiding ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Federal regulators shook up a rapidly growing pharmaceutical marketplace when they announced that tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, was no longer in shortage ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

Like many health plans, Lilla’s insurance didn’t cover Wegovy for weight loss use. Out of pocket, a month’s supply came with a price tag of more than $1,300. Even after applying a coupon from the drug ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give ...

The order would prevent the FDA from enforcing restrictions on compounding against larger facilities that have made copies of Lilly’s Mounjaro and Zepbound for telehealth ... tread lightly on ...

A recent study published by the Journal of the American Medical Association (JAMA) found that patients taking the drugs ...